Drugs Xagena
The FDA ( Food and Drug Administration ) has assigned Priority Review to the regulatory submission for Ramucirumab as a single-agent treatment for advanced gastric cancer following disease progression ...
Eli Lilly has announced that the REVEL trial, a global phase III study of Ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer ( NSCLC ), showed a stati ...
The U.S. Food and Drug Administration ( FDA ) has approved Cyramza ( Ramucirumab injection, 10 mg/mL solution ), as a single agent, for the treatment of patients with hepatocellular carcinoma ( HCC ) ...
